Media Articles Related to Trelstar Depot (Triptorelin)
WSU researchers show how fatty acids can fight prostate cancer
Source: Nutrition / Diet News From Medical News Today [2015.03.20]
Mechanism points way to more effective drug treatmentWashington State University researchers have found a mechanism by which omega-3 fatty acids inhibit the growth and spread of prostate cancer...
Study identifies 'lethal' subtype of prostate cancer
Source: Genetics News From Medical News Today [2015.03.19]
7,500 deaths per year possibly due to MAP3K7-CHD1 lossA University of Colorado Cancer Center study published in the journal Cancer Research defines a new, distinct subtype of "lethal" prostate...
Predicting prostate cancer
Source: Prostate / Prostate Cancer News From Medical News Today [2015.03.19]
Nanotechnology shows promise for more accurate prostate cancer screening and prognosisA Northwestern University-led study in the emerging field of nanocytology could one day help men make better...
Inappropriate breast, prostate cancer imaging 'may be driven by regional factors'
Source: Breast Cancer News From Medical News Today [2015.03.15]
Regional culture and infrastructure may be behind high rates of inappropriate breast and prostate cancer imaging, finds a new study.
VolitionRx initiates second prostate cancer pilot study assessing Nucleosomics(R) technology
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.03.10]
VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has initiated a pilot...
Published Studies Related to Trelstar Depot (Triptorelin)
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. [2011.07.20]
CONTEXT: Premenopausal patients with breast cancer are at high risk of premature ovarian failure induced by systemic treatments, but no standard strategies for preventing this adverse effect are yet available. OBJECTIVE: To determine the effect of the temporary ovarian suppression obtained by administering the gonadotropin-releasing hormone analogue triptorelin during chemotherapy on the incidence of early menopause in young patients with breast cancer undergoing adjuvant or neoadjuvant chemotherapy... CONCLUSION: The use of triptorelin-induced temporary ovarian suppression during chemotherapy in premenopausal patients with early-stage breast cancer reduced the occurrence of chemotherapy-induced early menopause. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00311636.
A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis. [2011.07]
PURPOSE: To compare the role of an aromatase inhibitor (letrozole) with a GnRH agonist (triptorelin) versus case control on the pregnancy rate and recurrence of symptoms and signs in patients with endometriosis... CONCLUSION: Pregnancy rate and endometriosis recurrence rate are comparable among the 3 groups.
Synchronization of ovulation and fertility in weaned sows treated with intravaginal triptorelin is influenced by timing of administration and follicle size. [2011.01.15]
A 100 mug dose of triptorelin was tested for synchronizing ovulation in sows. In Experiment 1, conducted in April through June, sows (n = 125) were assigned to Control (untreated), TG-96 (Triptorelin Gel (TG) given intravaginally at 96 h post-weaning), or TG-E (given intravaginally at estrus)... However, ovulation induction and timed AI success may benefit from an approach that ensures sows have adequate follicle development at time of treatment.
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. [2010.01]
OBJECTIVE: To examine and compare the efficacy and safety of GnRH agonist (GnRHa) vs. aromatase inhibitor in premenopausal women with leiomyomas.
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. [2009.01.08]
OBJECTIVE: To examine and compare the efficacy and safety of GnRH agonist (GnRHa) vs. aromatase inhibitor in premenopausal women with leiomyomas.Rapid onset of action and avoidance of initial gonadotropin flare with an aromatase inhibitor may be advantageous for short-term management of women with myomas of any size who are to be managed transiently and who wish to avoid surgical intervention, specifically women with unexplained infertility having uterine myoma.
Clinical Trials Related to Trelstar Depot (Triptorelin)
Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg [Recruiting]
The purpose of this study is to demonstrate the pharmacodynamic equivalence of triptorelin
pamoate (Pamorelin® LA 11. 25 mg), applied either IM or SC, in terms of the area under the
curve [AUC1-85day] for serum testosterone in patients with advanced prostate cancer.
Study to Assess the Non-Inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT) [Recruiting]
The active ingredient of Pamorelin® 11,25 mg is Triptorelin. Triptorelin is a substitute for
a natural hormone produced in the body called Gonadotrophin-releasing hormone (GnRH). GnRH is
a hormone secreted by hypothalamus (a gland located in brain) and controls the production of
sex hormones (eg testosterone in men) in other organs in the body. The growth of prostate
cancer cells, one of the most common cancers in men, is induced by the hormone testosterone.
Hormono-therapy is one of treatments available to treat this type of disease by controlling
the testosterone serum level. Pamorelin® 11,25 mg is normally injected in the muscle but
this type of injection is not suitable for every patient. Therefore the primary purpose of
this study is to assess the non-inferiority of the 12-week triptorelin formulation PamorelinÂ®
11,25 mg administered via subcutaneous (SC) injection as compared to PamorelinÂ® 11,25 mg
administered via standard intramuscular (IM) injection based on the percentage of patients
presenting a testosterone level â‰¤ 50 ng/dl at week 24.
Efficacy, Safety, and PK of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty [Recruiting]
The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22. 5 mg
6-month formulation in 44 patients suffering from central precocious puberty. The null
hypothesis of the study is that the proportion of patients achieving LH suppression to
prepubertal levels at Month 6 is 80%.
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer [Recruiting]
The study will investigate the efficacy, pharmacokinetics and safety of triptorelin embonate
22. 5 mg 6-month formulation administered by subcutaneous injections in patients with
Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty [Recruiting]
The purpose of the study is to assess the efficacy of triptorelin 11. 25 mg pamoate in the
delay of premature onset of puberty in girls less than 9 years and boys less than 10 years.
This is measured by assessing the proportion of children who have a suppressed Luteinizing
Hormone (LH) response to Gonadotropin Releasing Hormone (GnRH) test performed 3 months after
injection with triptorelin 11. 25 mg.